BMS' Breyanzi (lisocabtagene maraleucel) Receives the US FDA's Approval for Adults With R/R Large-B-Cell Lymphoma
Shots:
- The approval is based on pivotal TRANSCEND NHL 001 (017001) study assessing Breyanzi in 268 patients with 3L+R/R LBCL including patients with a broad range of histologies and high-risk disease. Breyanzi was administered in the inpatient & outpatient settings
- Results: ORR (73%); CR (54%); PR (19%); mDOR (16.7mos.) in all responders; patients with best response or PR- mDOR (1.4mos.); patients achieving CR- 65% had remission lasting at least 6mos. and 62% had remission lasting at least 9mos.
- Breyanzi is a CD19-directed CAR T cell therapy with defined composition and 4-1BB costimulatory domain. Additionally- the US FDA has granted ODD- RMAT and BT Designation to the therapy
- Ref: PRNewswire | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com